The European Medicines verification organization (EMVO) has prepared an overview of the fee models of the national medicines verification organizations (NMVO) for 2026. The overview contains information that is particularly relevant for Marketing Authorization Holders (MAH), including the latest information on the entrance fee and the annual fee, as well as providing insight into the fixed and variable fee models applied in different countries.
The NMVO fee models overview table and the NMVO fee models overview presentation are available on the EMVO website: NMVO Fee Model 2026 – EMVO
As stipulated in the Falsified Medicines Directive and the Commission Delegated Regulation (EU) 2016/161, all MAHs must register with the national organizations responsible for establishing and maintaining the medicines verification system, sign a cooperation agreement with the NMVO, and make entrance and annual payments in accordance with the funding policy established in each country.
In Latvia, the established funding model provides for a one-time registration fee EUR 3000, as well as an annual fixed flat fee for each MAH. The amount of the annual fixed flat fee is variable and is approved by the members’ meeting of the Latvian Medicines verification organization (LZVO). LZVO informs all MAHs of the amount of the annual fixed flat fee for the following year no later than 30 November of the previous year. In 2026, the annual fixed fee for each MAH is EUR 2500.
Representatives of MAHs are invited to contact LZVO regarding the annual fee or other relevant matters by writing to: info@lzvo.lv